Navigation Links
Anthony S. Fauci, M.D., on results from the CAPRISA 004 microbicide study
Date:7/19/2010

Today we congratulate the Centre for the AIDS Programme of Research in South Africa (CAPRISA) and the people of South Africa on the positive findings from the CAPRISA 004 microbicide study, which marks a significant milestone both for the microbicide research field and HIV prevention as a whole.

For years, antiretroviral medicines have been effectively used to treat HIV infection. Through the successful conduct of the CAPRISA 004 study, we now have proof that an antiretroviral drug, in this case tenofovir, can be formulated into a vaginal gel that can protect women against HIV infection. Given that women make up the majority of new HIV infections throughout the world this finding is an important step toward empowering an at-risk population with a safe and effective HIV prevention tool.

The CAPRISA 004 study is an exciting scientific achievement that moves us one step forward to gaining another effective tool to prevent HIV infection. However, because no one approach will be appropriate or acceptable to all, we must continue to pursue a range of HIV prevention modalities, including microbicides, PrEP, and vaccines, as we simultaneously pursue scientific strategies designed to bring us closer to finding a cure for HIV/AIDS.

The daunting nature of the HIV/AIDS pandemic makes it clear that no single organization can tackle the problem alone. The CAPRISA 004 study is an excellent example of what researchers, governments, countries, industry, communities and individual study volunteers can accomplish when working together to find public health solutions. NIAID is proud to be among the many partner organizations that provided significant support and resources to establish the infrastructure and training necessary to conduct this landmark clinical trial.

Now we must build upon the CAPRISA research and identify a highly effective and acceptable microbicide for women and other groups at high-risk for HIV infection. The NIAID-sponsored VOICE study (http://www.niaid.nih.gov/news/newsreleases/2009/Pages/VOICE.aspx), which launched last fall and is expected to enroll 5,000 women in four south African countries, will provide additional safety and effectiveness data for a tenofovir-based vaginal gel as an HIV prevention method. The study also will offer some insight as to the gel's acceptability as a product used once a day rather than one that is used before and after sexual intercourse. Additionally, the VOICE study is examining oral antiretroviral tablets (tenofovir alone or tenofovir plus emtricitabine) as an HIV prevention method. This approach is known as pre-exposure prophylaxis, or PrEP. NIAID and other research organizations are exploring PrEP strategies in studies involving a number of at-risk populations with the first results expected early next year.


'/>"/>

Contact: Laura Sivitz Leifman
sivitzl@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Stanford Who's Who & Anthony Casimano Make Donation to Help Support National Organization, CancerCare
2. Elizabeth Glaser Pediatric AIDS Foundation President and CEO Charles Lyons Welcomes the Appointment of Anthony Lake as New Executive Director of UNICEF
3. ISSA Applauds Cincinnati Trainer Anthony Reed for Dedication to Health Awareness
4. Renowned Psychiatrist, Lyubov Y Gorelik, M.D., is selected to represent New York in The Leading Physicians of the World
5. Gino Tutera, M.D., F.A.C.O.G. Brings SottoPelle Therapy to Middle Tennessee, Opens Practice in Nashville Medical District
6. Joan Miller, M.D., receives 2010 Leadership Award for the Advancement of Women Faculty
7. University of Utah afib specialist, Marcos Daccarett, M.D., wins Young Investigator Award
8. Nationally Known Interventional Neuroradiologist John Pile-Spellman, M.D., Joins Neurological Surgery, P.C.
9. AMA Honors Vice Admiral John Mateczun, M.D., With Top Government Service Award
10. Many False-Positive HIV Test Results for Those in AIDS Vaccine Trials
11. FDA Reviewer Questions Results of Key Avandia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Brenntag Specialties, Inc.(BSI) ... Food & Beverage and Dietary Supplement market segments across ... and USA geographies east of the Rocky Mountains since 2012. Consistent performance ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... BantamPro L top-load case packer for pouches, bags, and flow wrapped products at ... help co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... community enrichment program serving the greater Venice, FL area, has initiated a fundraiser ... in a car accident just four days after Christmas. To support this beautiful ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... of organizations. DocuSyst provides a cloud hosted environment for FileHold software that ... integration with various 3rd party applications using the FileHold web services API. DocuSyst ...
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... CARLSBAD, Calif. , Feb. 8, 2016  HemaFlo Therapeutics, ... Office (USPTO) has issued US Patent Number 9,119,880 covering the ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ... technology." --> Dale Peterson , PhD, HemaFlo,s ... such a powerful technology." --> Dale ...
(Date:2/8/2016)... 8, 2016  Dynatronics Corporation (NASDAQ: DYNT ... devices and rehabilitation equipment for the physical therapy, ... Broncos, football team for winning the 2016 World ... Chairman and Chief Executive Officer.  "The Broncos have ... forward to enhancing their athletic achievements with our ...
(Date:2/8/2016)... RICHMOND, Calif. , Feb. 8, 2016 /PRNewswire/ ... leader in therapeutic genome editing, announced that the ... the Company,s Investigational New Drug (IND) application for ... a life-long therapy for Mucopolysaccharidosis Type I (MPS ... and enables Sangamo to initiate a Phase 1/2 ...
Breaking Medicine Technology: